Combination therapy study for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that is advanced or cannot be removed by surgery.
- You have not had any prior treatment for advanced esophageal cancer.
- You are willing to provide a tumor sample for testing.
- You have an ECOG performance status of 0 or 1 (meaning you are fully active or only have mild symptoms).
- You have adequate organ function based on blood and urine tests.
- You have no other cancer that has required treatment in the past 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This trial tests a combination of three drugs—becotatug vedotin, tislelizumab, and low-dose lenvatinib—for people with advanced esophageal cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of a new drug (SYS6010), an immunotherapy called enlonstobart, and standard chemotherapy as the first treatment for esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.